<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="55343">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01926132</url>
  </required_header>
  <id_info>
    <org_study_id>3-2012-0154</org_study_id>
    <nct_id>NCT01926132</nct_id>
  </id_info>
  <brief_title>High-dose Ascorbic Acid Intravenous Injection Decreases Mitochondrial DNA Damage in Chronic Fatigue Patients: Randomized-controlled Study</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <authority>Korea: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Reactive Oxygen Species (ROS) can cause oxidative damage, resulting in oxidation of lipids,
      proteins and DNA. In fatigue patients, there are some evidences of oxidative damage to DNA.
      Ascorbic acid was known to protect mitochondrial injury against oxidative stress by
      depolarizing the mitochondrial membrane. The copy number of mitochondrial DNA(mtDNA) was
      suggested mitochondrial gene stability and biogenesis and reflected mitochondrial function.
      There is no evidence ascorbic acid would decrease the mtDNA damage in fatigue patients. The
      investigators hypothesized that decreasing in mtDNA copy number in salivary and blood sample
      may be reversed by high-dose vitamin C intravenous injection in fatigue patients. The
      investigators will compare the mtDNA copy number and fatigue scale between moderate-severe
      fatigue patients and control group that had not malignant and chronic illness by a
      randomized controlled trial.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">October 2013</completion_date>
  <primary_completion_date type="Anticipated">October 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>fatigue scale</measure>
    <time_frame>2 weeks after 10g ascorbic aicd intravenous injection</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>mitochondrial DNA copy number on blood and salivary samples</measure>
    <time_frame>2 weeks after 10g ascorbic aicd intravenous injection</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Chronic Fatigue</condition>
  <arm_group>
    <arm_group_label>ascorbic acid 10g/20ml</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Normal Saline 130ml+ ascorbic acid 10g/20ml , covered bottle for the blind allocation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Saline 150ml</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Normal Saline 150ml, covered bottle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ascorbic acid 10g/20ml</intervention_name>
    <description>ascorbic acid 10g/20cc intravenous injection for 40mins</description>
    <arm_group_label>ascorbic acid 10g/20ml</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal Saline 150ml</intervention_name>
    <description>Normal Saline 150ml intravenous injection for 40mins</description>
    <arm_group_label>Normal Saline 150ml</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adults with above 18 years old and 6 month fatigue duration

          2. Moderate to severe fatigue scale (Brief fatigue inventory-Korean version scale â‰¥ 4)

          3. Normal limit values in the screening test (White blood cell count, Hemoglobin,
             Creatinine, SGOT/SGPT, Thyroid stimulating hormone, Urinalysis)

          4. Normal limit values in glucose 6 phosphate dehydrogenase level

          5. Agree the subjects explanation

        Exclusion Criteria:

          1. pregnancy and lactation

          2. acute common cold, acute gastroenteritis, uncontrolled diabetes, uncontrolled
             hypertension, liver disease or renal disease

          3. previous medical history, affectable by high-dose ascorbic acid (gout, renal calculi
             and glucose 6 phosphate dehydrogenase deficiency)

          4. hypersensitivity from ascorbic acid

          5. vitamin supplement intake until 2 days ago

          6. drug interactions with ascorbic acid ( aspirin, Fe, phenytoin, estrogen,
             tetracycline, coumarin, corticosteroid)

          7. Do not read a consent fom
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jae Yong Shim, MD</last_name>
    <phone>82-2-2019-3480</phone>
    <email>hope@yuhs.ac</email>
  </overall_contact>
  <location>
    <facility>
      <name>Gangnam Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>135-720</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jae Yong Shim, MD</last_name>
      <phone>82-2-2019-3480</phone>
      <email>hope@yuhs.ac</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 19, 2013</lastchanged_date>
  <firstreceived_date>August 16, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ascorbic acid</keyword>
  <keyword>fatigue</keyword>
  <keyword>mitochondrial DNA</keyword>
  <keyword>patient for more than 6 months</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fatigue</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ascorbic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
